Lindén V, Christensen K K, Christensen P
Int Arch Allergy Appl Immunol. 1982;68(3):193-5. doi: 10.1159/000233096.
53 different batches of commercial IgG were tested for antibodies to group B streptococci (GBS) types Ia, Ib, II and III. The levels of antibodies varied widely. Comparison of the anti-GBS antibody levels in these preparations with those found in normal blood donor sera showed that the commercial IgG contained approximately 2.6 times less type-specific antibodies. We conclude that the commercial IgG now available is not optimal for passive immunization against GBS infections in neonates.
对53批市售免疫球蛋白G（IgG）进行了检测，以确定其针对B族链球菌（GBS）Ia、Ib、II和III型的抗体情况。抗体水平差异很大。将这些制剂中的抗GBS抗体水平与正常献血者血清中的抗体水平进行比较后发现，市售IgG中特定类型的抗体含量约少2.6倍。我们得出结论，目前可用的市售IgG并非用于新生儿被动免疫预防GBS感染的最佳选择。
